{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:06:14Z","timestamp":1792112774557,"version":"4.4.0"},"reference-count":172,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1038\/ajg.2017.154","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T08:00:50Z","timestamp":1497945650000},"page":"988-1013","source":"Crossref","is-referenced-by-count":605,"title":["ACG and CAG Clinical Guideline: Management of Dyspepsia"],"prefix":"10.14309","volume":"112","author":[{"given":"Paul M","family":"Moayyedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher N","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A","family":"Enns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimish","family":"Vakil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-10-20210210","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2036.2006.03076.x","article-title":"Three centuries of stomach symptoms.","volume":"24","author":"Baron","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R4-10-20210210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2014-307843","article-title":"Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis.","volume":"64","author":"Ford","year":"2015","journal-title":"Gut"},{"key":"R5-10-20210210","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/ajg.2012.69","article-title":"Effect of dyspepsia on survival: a longitudinal 10-year follow up study.","volume":"107","author":"Ford","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R6-10-20210210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gut.2006.099846","article-title":"Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study.","volume":"56","author":"Ford","year":"2007","journal-title":"Gut"},{"key":"R7-10-20210210","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2036.2011.04789.x","article-title":"Randomised clinical trial: the burden of illness of univestigated dyspepsia before and after treatment with esomeprazoleresults from the STARS II study.","volume":"34","author":"Veldhuyzen van Zanten","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-10-20210210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/apt.12355","article-title":"Functional dyspepsia: the economic impact to patients.","volume":"38","author":"Lacy","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 4","key":"R9-10-20210210","first-page":"10","article-title":"Clinical and economic consequences of dyspepsia in the community.","volume":"50","author":"Moayyedi","year":"2002","journal-title":"Gut"},{"key":"R10-10-20210210","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1572-0241.2005.00225.x","article-title":"Guidelines for the management of dyspepsia.","volume":"100","author":"Talley","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R11-10-20210210","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2005\/674607","article-title":"Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool.","volume":"19","author":"Veldhuyzen van Zanten","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"R12-10-20210210","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2005.09.020","article-title":"American gastroenterological association technical review on the evaluation of dyspepsia.","volume":"129","author":"Talley","year":"2005","journal-title":"Gastroenterology"},{"key":"R13-10-20210210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(88)91364-5","article-title":"Management of dyspepsia: report of a working party.","volume":"331","author":"Colin-Jones","year":"1988","journal-title":"Lancet"},{"key":"R14-10-20210210","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1053\/j.gastro.2016.02.011","article-title":"Gastroduodenal disorders.","volume":"150","author":"Stanghellini","year":"2016","journal-title":"Gastroenterology"},{"key":"R15-10-20210210","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1053\/j.gastro.2005.11.059","article-title":"Functional gastroduodenal disorders.","volume":"130","author":"Tack","year":"2006","journal-title":"Gastroenterology"},{"key":"R16-10-20210210","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ajg.2013.89","article-title":"Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification.","volume":"108","author":"Vakil","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R17-10-20210210","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Diagnosis and management of gastroesophageal reflux disease.","volume":"108","author":"Katz","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R18-10-20210210","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","article-title":"The Toronto consensus for the treatment of Helicobacter pylori infection in adults.","volume":"151","author":"Fallone","year":"2016","journal-title":"Gastroenterology"},{"key":"R19-10-20210210","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R20-10-20210210","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"Rating quality of evidence and strength of recommendations: What is quality of evidence and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R21-10-20210210","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Rating quality of evidence and strength of recommendations: going from evidence to recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R23-10-20210210","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/pgmj.2004.031104","article-title":"Endoscopy waiting times and impact of the two week wait scheme on diagnosis and outcome of upper gastrointestinal cancer.","volume":"81","author":"Spahos","year":"2005","journal-title":"Postgrad Med J"},{"key":"R24-10-20210210","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/1055-9965.EPI-10-0012","article-title":"Esophageal adenocarcinoma incidence: are we reaching the peak?","volume":"19","author":"Pohl","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R25-10-20210210","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/gut.36.3.462","article-title":"Prospective audit of upper gastrointestinal endoscopy in two regions of England: safety, staffing and sedation methods.","volume":"36","author":"Quine","year":"1995","journal-title":"Gut"},{"key":"R26-10-20210210","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.gie.2012.03.252","article-title":"Adverse events of upper GI endoscopy.","volume":"76","author":"Ben-Menachem","year":"2012","journal-title":"Gastrointest Endosc"},{"key":"R27-10-20210210","first-page":"33","article-title":"Cost effectiveness analysis: applications.","volume":"28","author":"Barton","year":"2008","journal-title":"Med Decision Making"},{"key":"R30-10-20210210","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.cgh.2009.03.031","article-title":"Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms.","volume":"7","author":"Vakil","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R32-10-20210210","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2006.04.029","article-title":"Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis.","volume":"131","author":"Vakil","year":"2006","journal-title":"Gastroenterology"},{"key":"R33-10-20210210","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.295.13.1566","article-title":"Can the clinical history distinguish between organic and functional dyspepsia?","volume":"295","author":"Moayyedi","year":"2006","journal-title":"JAMA"},{"key":"R34-10-20210210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ejca.2012.10.023","article-title":"Identifying patients with undetected gastro-oesophageal cancer in primary care: external validation of QCancer (Gastro-Oesophageal).","volume":"49","author":"Collins","year":"2013","journal-title":"Eur J Cancer"},{"key":"R35-10-20210210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/bmj.39171.637106.AE","article-title":"Alarm symptoms in early diagnosis of cancer in primary care cohort study using General Practice Research Database.","volume":"334","author":"Jones","year":"2007","journal-title":"BMJ"},{"key":"R36-10-20210210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/bjc.2012.551","article-title":"The risk of oesophago-gastric cancer in symptomatic patients in primary care: a large case-control study using electronic records.","volume":"108","author":"Stapley","year":"2013","journal-title":"Br J Cancer"},{"key":"R38-10-20210210","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/gut.45.2.186","article-title":"A prospective randomised trial of a test and treat policy versus endoscopy based management in young Helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic.","volume":"45","author":"Heaney","year":"1999","journal-title":"Gut"},{"key":"R39-10-20210210","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(00)02553-8","article-title":"Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial.","volume":"356","author":"Lassen","year":"2000","journal-title":"Lancet"},{"key":"R40-10-20210210","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.324.7344.999","article-title":"Randomised controlled trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia.","volume":"324","author":"McColl","year":"2002","journal-title":"BMJ"},{"key":"R41-10-20210210","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/archinte.163.13.1606","article-title":"Approach to treatment of dyspepsia in primary care: a randomised trial comparing test and treat with prompt endoscopy.","volume":"163","author":"Arents","year":"2003","journal-title":"Arch Intern Med"},{"key":"R42-10-20210210","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1136\/gut.2007.147728","article-title":"Cost-effectiveness of and satisfaction with a Helicobacter pylori test and treat strategy compared with prompt endoscopy in young Asians with dyspepsia.","volume":"57","author":"Mahadeva","year":"2008","journal-title":"Gut"},{"key":"R43-10-20210210","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2036.2008.03852.x","article-title":"Clinical trial: a randomized trial of early endoscopy, Helicobacter pylori testing and empirical therapy for the management of dyspepsia in primary care.","volume":"29","author":"Duggan","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R45-10-20210210","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/bmj.324.7344.1012","article-title":"Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatmentHelicobacter pylori positive (CADET-HP) randomised controlled trial.","volume":"324","author":"Chiba","year":"2002","journal-title":"BMJ"},{"key":"R47-10-20210210","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/bmj.326.7399.1118","article-title":"Empirical prescribing for dyspepsia: randomised controlled trial of test and treat versus omeprazole treatment.","volume":"326","author":"Manes","year":"2003","journal-title":"BMJ"},{"key":"R48-10-20210210","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ajg2006227","article-title":"Proton pump inhibitor or testing for Helicobacter pylori as the first step for patients presenting with dyspepsia? A cluster-randomized trial.","volume":"101","author":"Jarbol","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R49-10-20210210","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1136\/bmj.39479.640486.AE","article-title":"Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial).","volume":"336","author":"Delaney","year":"2008","journal-title":"BMJ"},{"key":"R50-10-20210210","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2036.2008.03784.x","article-title":"Meta-analysis: H. pylori\"test and treat\" compared with empirical acid suppression for managing dyspepsia?","volume":"28","author":"Ford","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R51-10-20210210","first-page":"CD005583","article-title":"Helicobacter pylori eradication for the prevention of gastric cancer.","volume":"7","author":"Ford","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R52-10-20210210","doi-asserted-by":"crossref","first-page":"g3174","DOI":"10.1136\/bmj.g3174","article-title":"Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials.","volume":"348","author":"Ford","year":"2014","journal-title":"BMJ"},{"key":"R53-10-20210210","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/13814789709160347","article-title":"Antisecretory therapy in 1017 patients with ulcerlike or reflux-like dyspepsia in general practice.","volume":"3","author":"Meineche-Schmidt","year":"1997","journal-title":"Eur J General Pract"},{"key":"R54-10-20210210","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2036.1998.0284f.x","article-title":"First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacidalginate liquid: a multicentre study in general practice.","volume":"12","author":"Goves","year":"1998","journal-title":"Alimen Pharmacol Ther"},{"key":"R55-10-20210210","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1111\/j.1572-0241.2002.07123.x","article-title":"A double blind, randomized, placebo-controlled trial of proton pump inhibitor therapy in patients with uninvestigated dyspepsia.","volume":"97","author":"Rabeneck","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R56-10-20210210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1572-0241.2004.30089.x","article-title":"Empiric treatment with high and standard dose of Omeprazole in General Practice: two-week randomised placebo controlled trial and 12 month follow up of healthcare consumption.","volume":"99","author":"Meineche-Schmidt","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R57-10-20210210","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1572-0241.2005.40280.x","article-title":"A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in Helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.","volume":"100","author":"Veldhuyzen van Zanten","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R58-10-20210210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5152\/tjg.2015.0010","article-title":"Effect of pantoprazole and Helicobacter pylori therapy on uninvestigated dyspeptic patients.","volume":"26","author":"Baysal","year":"2015","journal-title":"Turk J Gastroenterol"},{"key":"R59-10-20210210","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1046\/j.1365-2036.1997.00179.x","article-title":"Lansoprazole 30mg daily versus ranitidine 150mg b.d. in the treatment of acid-related dyspepsia in general practice.","volume":"11","author":"Jones","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R60-10-20210210","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2036.1998.00282.x","article-title":"The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginateranitidine management strategy. Complete Research Group.","volume":"12","author":"Mason","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"R61-10-20210210","doi-asserted-by":"crossref","first-page":"640685","DOI":"10.1155\/2011\/640685","article-title":"Lafutidine 10mg versus rabeprazole 20mg in the treatment of patients with heartburn-dominant uninvestigated dyspepsia: a randomized, multicentric trial.","volume":"2011","author":"Dewan","year":"2011","journal-title":"Gastroenterol Res Pract"},{"key":"R62-10-20210210","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1471-230X-12-42","article-title":"Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS).","volume":"12","author":"Sakurai","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"R63-10-20210210","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4103\/0253-7613.140580","article-title":"Randomized controlled trial of effectiveness of lafutidine versus pantoprazole in uninvestigated dyspepsia.","volume":"46","author":"Maity","year":"2014","journal-title":"Indian J Pharmacol"},{"key":"R64-10-20210210","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(94)92023-0","article-title":"Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia.","volume":"343","author":"Bytzer","year":"1994","journal-title":"Lancet"},{"key":"RU65-10-20210210","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/S0140-6736(00)03308-0","article-title":"Cost-effectiveness of initial endoscopy for dyspepsia in patients over the age of 50 years: a randomised controlled trial in primary care.","volume":"356","author":"Delaney","year":"2000","journal-title":"Lancet"},{"key":"R66-10-20210210","first-page":"619","article-title":"A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.","volume":"51","author":"Lewin-van den Broek","year":"2001","journal-title":"Br J General Pract"},{"key":"R67-10-20210210","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1017\/S0266462307070420","article-title":"Cost-effectiveness analysis of two management strategies for dyspepsia.","volume":"23","author":"Kjeldsen","year":"2007","journal-title":"Int J Technol Assess Health Care"},{"key":"R68-10-20210210","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(06)68932-0","article-title":"Gastro-esophageal reflux disease.","volume":"367","author":"Moayyedi","year":"2006","journal-title":"Lancet"},{"key":"R72-10-20210210","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/gutjnl-2015-310721","article-title":"Efficacy of psychotic drugs in functional dyspepsia: systematic review and meta-analysis.","volume":"66","author":"Ford","year":"2016","journal-title":"Gut"},{"key":"R73-10-20210210","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.cgh.2010.05.031","article-title":"What is the prevalence of clinically significant endoscopic finding in subjects with dyspepsia? Systematic review and meta-analysis.","volume":"8","author":"Ford","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R74-10-20210210","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrgastro.2013.9","article-title":"Helicobacter pylori infection in functional dyspepsia.","volume":"10","author":"Suzuki","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R75-10-20210210","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00535-006-1818-x","article-title":"Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.","volume":"41","author":"Ang","year":"2006","journal-title":"J Gastroenterol"},{"key":"R76-10-20210210","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJM199812243392602","article-title":"Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxycillin Effect One Year after Treatment (OCAY) Study Group.","volume":"339","author":"Blum","year":"1998","journal-title":"N Engl J Med"},{"key":"R77-10-20210210","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/j.1572-0241.2001.04037.x","article-title":"Helicobacter pylori eradication treatment does not benefit patients with non-ulcer dyspepsia.","volume":"96","author":"Froehlich","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R78-10-20210210","first-page":"303","article-title":"Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study.","volume":"51","author":"Gisbert","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"R79-10-20210210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0025-7753(04)74153-6","article-title":"Efficacy of Helicobacter pylori eradication in non-ulcer dyspepsia.","volume":"122","author":"Gonzalez Carro","year":"2004","journal-title":"Med Clin"},{"key":"R80-10-20210210","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/MEG.0b013e328317b89e","article-title":"The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.","volume":"21","author":"Gwee","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R81-10-20210210","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1046\/j.1365-2036.2001.00903.x","article-title":"Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia.","volume":"15","author":"Hsu","year":"2001","journal-title":"Aliment Pharmacol Therap"},{"key":"R82-10-20210210","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gut.52.1.40","article-title":"Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up.","volume":"52","author":"Koelz","year":"2003","journal-title":"Gut"},{"key":"R83-10-20210210","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1111\/j.1572-0241.2001.04240.x","article-title":"Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.","volume":"96","author":"Koskenpato","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R84-10-20210210","first-page":"3242","article-title":"Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia.","volume":"17","author":"Lan","year":"2011","journal-title":"World J Gastroenterol"},{"key":"R85-10-20210210","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1365-2036.2003.01695.x","article-title":"Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.","volume":"18","author":"Malfertheiner","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R86-10-20210210","first-page":"25","article-title":"Effect of eradicating H. pylori on the appearance of esophageal reflux disease: randomized double blind study.","volume":"85","author":"Martinek","year":"2005","journal-title":"Prakt Lek"},{"key":"R87-10-20210210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10620-006-3090-6","article-title":"Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.","volume":"51","author":"Mazzoleni","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R88-10-20210210","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/archinternmed.2011.533","article-title":"Helicobacter pylori eradication in functional dyspepsia: HEROES trial.","volume":"171","author":"Mazzoleni","year":"2011","journal-title":"Arch Intern Med"},{"key":"R89-10-20210210","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJM199812243392601","article-title":"Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.","volume":"339","author":"McColl","year":"1998","journal-title":"N Engl J Med"},{"key":"R90-10-20210210","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2036.2000.00706.x","article-title":"Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study.","volume":"14","author":"Miwa","year":"2000","journal-title":"Aliment Pharmacol Therap"},{"key":"R91-10-20210210","first-page":"401","article-title":"Effect of the Helicobacter pylori eradication in patients with functional dyspepsia: randomised placebo-controlled trial.","volume":"124","author":"Ruiz Garcia","year":"2005","journal-title":"Med Clin"},{"key":"R92-10-20210210","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/jgh.12178","article-title":"Prevalence of Helicobacter pylori infection and the effect of its eradication on symptoms of functional dyspepsia in Kashmir, India.","volume":"28","author":"Sodhi","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R93-10-20210210","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.318.7187.833","article-title":"Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trials with 12 months follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group.","volume":"318","author":"Talley","year":"1999","journal-title":"Br Med J"},{"key":"R94-10-20210210","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199910073411502","article-title":"Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.","volume":"341","author":"Talley","year":"1999","journal-title":"N Engl J Med"},{"key":"R95-10-20210210","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/S0002-9270(03)00432-5","article-title":"Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.","volume":"98","author":"Veldhuyzen van Zanten","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R96-10-20210210","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1046\/j.1365-2036.2001.01014.x","article-title":"There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia.","volume":"15","author":"Bruley Des Varannes","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R97-10-20210210","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/bmj.321.7262.659","article-title":"Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia.","volume":"321","author":"Moayyedi","year":"2000","journal-title":"Br Med J"},{"key":"R98-10-20210210","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1001\/archinternmed.2011.541","article-title":"Helicobacter pylori eradication for functional dyspepsia: what are we treating?","volume":"171","author":"Moayyedi","year":"2011","journal-title":"Arch Intern Med"},{"key":"R99-10-20210210","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1440-1746.2009.06143.x","article-title":"Evaluation of duodenal hypersensitivity induced by duodenal acidification using transnasal endoscopy.","volume":"25","author":"Ishii","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R100-10-20210210","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/gut.47.4.473","article-title":"Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status.","volume":"47","author":"Blum","year":"2000","journal-title":"Gut"},{"key":"R101-10-20210210","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/003655202762671260","article-title":"Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial.","volume":"37","author":"Bolling-Sternevald","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"R102-10-20210210","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/003655299750026029","article-title":"Patients with functional dyspepsia responding to omeprazole have a characteristic gastro-oesophageal reflux pattern.","volume":"34","author":"Farup","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"R103-10-20210210","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/gut.2010.228064","article-title":"BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy.","volume":"60","author":"Fletcher","year":"2011","journal-title":"Gut"},{"key":"R104-10-20210210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.dld.2004.09.021","article-title":"A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia.","volume":"37","author":"Gerson","year":"2005","journal-title":"Dig Liver Dis"},{"key":"R105-10-20210210","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/apt.12444","article-title":"Randomised clinical trial: rabeprazole improves symptoms in patients with functional dyspepsia in Japan.","volume":"38","author":"Iwakiri","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"R106-10-20210210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.amjmed.2004.01.008","article-title":"Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials.","volume":"116","author":"Peura","year":"2004","journal-title":"Am J Med"},{"key":"R107-10-20210210","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/2050640613510904","article-title":"Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): a multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.","volume":"1","author":"Suzuki","year":"2013","journal-title":"United Eur Gastroenterol J"},{"key":"R108-10-20210210","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1046\/j.1365-2036.1998.00410.x","article-title":"Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies).","volume":"12","author":"Talley","year":"1998","journal-title":"Aliment Pharmacol Ther"},{"key":"R109-10-20210210","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2036.2007.03410.x","article-title":"Randomized-controlled trial of esomeprazole in functional dyspepsia patients with epigastric pain or burning: does a 1-week trial of acid suppression predict symptom response?","volume":"26","author":"Talley","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R110-10-20210210","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1185\/03007990802184545","article-title":"Efficacy and safety of pantoprazole 20mg once daily treatment in patients with ulcer-like functional dyspepsia.","volume":"24","author":"van Rensburg","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"R111-10-20210210","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/j.1572-0241.2006.00751.x","article-title":"Esomeprazole 40mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled ENTER trial.","volume":"101","author":"van Zanten","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R112-10-20210210","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/gut.51.4.502","article-title":"Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients.","volume":"51","author":"Wong","year":"2002","journal-title":"Gut"},{"issue":"Suppl 2","key":"R113-10-20210210","first-page":"A89","article-title":"Therapeutic efficacy of 15mg lansoprazole mane in 269 patients suffering from non-ulcer dyspepsia (NUD): a multicentre, randomised, double-blind study.","volume":"43","author":"Hengels","year":"1998","journal-title":"Gut"},{"issue":"Suppl 6","key":"R114-10-20210210","first-page":"A285","article-title":"A comparison of lansoprazole vs. ranitidine in the treatment of functional ulcer-like dyspepsia as defined by Rome II criteria.","volume":"53","author":"Dillon","year":"2004","journal-title":"Gut"},{"key":"R115-10-20210210","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00535-010-0334-1","article-title":"Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is a therapeutic response predicted by Rome III subgroups?","volume":"46","author":"Hsu","year":"2011","journal-title":"J Gastroenterol"},{"key":"R116-10-20210210","first-page":"547","article-title":"Comparison of mosapride and pantoprazole in treating functional dyspepsia.","volume":"16","author":"Jian","year":"2011","journal-title":"Chin J Gastroenterol"},{"key":"R117-10-20210210","doi-asserted-by":"crossref","first-page":"254","DOI":"10.5056\/jnm15178","article-title":"Efficacy of DA-9701 (Motilitone) in Functional Dyspepsia Compared to Pantoprazole: A Multicenter, Randomized, Double-blind, Non-inferiority Study.","volume":"22","author":"Jung","year":"2016","journal-title":"J Neurogastroenterol Motil"},{"key":"R118-10-20210210","first-page":"337","article-title":"Low-dose omeprazole in the treatment of functional dyspepsia.","volume":"8","author":"Li","year":"2003","journal-title":"Chin J Gastroenterol"},{"key":"R119-10-20210210","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1053\/j.gastro.2004.08.026","article-title":"The efficacy of proton pump inhibitors in non-ulcer dyspepsia: a systematic review and economic analysis.","volume":"127","author":"Moayyedi","year":"2004","journal-title":"Gastroenterology"},{"key":"R120-10-20210210","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrgastro.2016.44","article-title":"Thearpy: risk associated with chronic PPI usesignal or noise?","volume":"13","author":"Kia","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R121-10-20210210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/nrgastro.2011.272","article-title":"The risks of PPI therapy.","volume":"9","author":"Moayyedi","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R122-10-20210210","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1155\/2013\/321379","article-title":"Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.","volume":"27","author":"Moayyedi","year":"2013","journal-title":"Can J Gastroenterol"},{"key":"R124-10-20210210","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/ajg.2014.148","article-title":"Effect of antidepressants and psychological therapies, including hypnotherapy, in irritable bowel syndrome: systematic review and meta-analysis.","volume":"109","author":"Ford","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"R125-10-20210210","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cgh.2009.07.020","article-title":"Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia.","volume":"8","author":"Ford","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R126-10-20210210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2036.2011.04775.x","article-title":"Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study.","volume":"34","author":"Braak","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R129-10-20210210","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.3748\/wjg.v18.i42.6127","article-title":"Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.","volume":"18","author":"Tan","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R130-10-20210210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/MOG.0b013e32834b7ca8","article-title":"Functional dyspepsia.","volume":"27","author":"Tack","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"R131-10-20210210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2012.05128.x","article-title":"Review article: current treatment options and management of functional dyspepsia.","volume":"36","author":"Lacy","year":"2012","journal-title":"Aliment Pharmacol Therap"},{"key":"R132-10-20210210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/00365529509089785","article-title":"A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia.","volume":"30","author":"Al-Quorain","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"R133-10-20210210","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1155\/1997\/314839","article-title":"A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group.","volume":"11","author":"Champion","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"R134-10-20210210","first-page":"749","article-title":"Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial. Scand J Gastroenterol Suppl 1993;195:11-14 Erratum in: Scand J Gastroenterol S","volume":"28","author":"Chung","year":"1993","journal-title":"uppl"},{"key":"R135-10-20210210","first-page":"1063","article-title":"Effect of the non-antidopaminergic drug cisapride on postprandial nausea.","volume":"36","author":"Creytens","year":"1984","journal-title":"Curr Therap Res"},{"key":"R136-10-20210210","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1046\/j.1365-2036.1997.117288000.x","article-title":"Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study.","volume":"11","author":"de Groot","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"key":"R137-10-20210210","first-page":"62","article-title":"Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride.","volume":"11","author":"De Nutte","year":"1989","journal-title":"Clin Ther"},{"key":"R138-10-20210210","first-page":"891","article-title":"Non-ulcer dyspepsia: effect of the gastrointestinal prokinetic drug cisapride.","volume":"41","author":"Francois","year":"1987","journal-title":"Curr Ther Res"},{"key":"R139-10-20210210","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2036.2002.01236.x","article-title":"Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study.","volume":"16","author":"Hallerback","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R140-10-20210210","first-page":"814","article-title":"Efficacy of cisapride in patients with non-ulcer dyspepsia.","volume":"42","author":"Hannon","year":"1987","journal-title":"Curr Ther Res"},{"key":"R141-10-20210210","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1572-0241.1998.00368.x","article-title":"Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.","volume":"93","author":"Hansen","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R142-10-20210210","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1046\/j.1365-2036.2002.01322.x","article-title":"A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia.","volume":"16","author":"Holtmann","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"R143-10-20210210","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMoa052639","article-title":"A placebo-controlled trial of itopride in functional dyspepsia.","volume":"354","author":"Holtmann","year":"2006","journal-title":"N Engl J Med"},{"key":"R144-10-20210210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2036.1995.tb00364.x","article-title":"Efficacy of cisapride therapy in functional dyspepsia.","volume":"9","author":"Kellow","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"R145-10-20210210","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2982.2009.01449.x","article-title":"Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia100mg tid is an optimal dosage.","volume":"22","author":"Matsueda","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"R146-10-20210210","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/gutjnl-2011-301454","article-title":"A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia.","volume":"61","author":"Matsueda","year":"2012","journal-title":"Gut"},{"key":"R147-10-20210210","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1038\/ajg.2009.427","article-title":"Efficacy of the 5-HT1A agonist tandospirone citrate in improving symptoms of patients with functional dyspepsia: a randomized controlled trial.","volume":"104","author":"Miwa","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R148-10-20210210","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3109\/00365528708991874","article-title":"Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial.","volume":"22","author":"Rosch","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"R149-10-20210210","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1046\/j.1365-2036.2000.00868.x","article-title":"Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial.","volume":"14","author":"Talley","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R150-10-20210210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2036.2001.00941.x","article-title":"A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"R151-10-20210210","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gut.2007.132449","article-title":"Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials.","volume":"57","author":"Talley","year":"2008","journal-title":"Gut"},{"key":"R152-10-20210210","first-page":"1906","article-title":"Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials.","volume":"103","author":"Vakil","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R153-10-20210210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/00365529309098322","article-title":"Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients.","volume":"195","author":"Wood","year":"1993","journal-title":"Scand J Gastroenterol Suppl"},{"key":"R154-10-20210210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1440-1746.1997.tb00338.x","article-title":"Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial.","volume":"12","author":"Yeoh","year":"1997","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"R155-10-20210210","first-page":"30","article-title":"Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying.","volume":"55","author":"Bekhti","year":"1979","journal-title":"Postgrad Med J"},{"issue":"Suppl 1","key":"R156-10-20210210","first-page":"1033","article-title":"Open and double blind clinical trials of domperidone in patients with unexplained nausea, vomiting, abdominal bloating and early satiety.","volume":"82","author":"Chey","year":"1982","journal-title":"Gastroenterology"},{"key":"R157-10-20210210","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/BF01535938","article-title":"Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind placebo- controlled study.","volume":"33","author":"Davis","year":"1988","journal-title":"Dig Dis Sci"},{"key":"R159-10-20210210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000198352","article-title":"Oral domperidone in chronic postprandial dyspepsia.","volume":"19","author":"Van de Mierop","year":"1979","journal-title":"Digestion"},{"key":"R160-10-20210210","first-page":"695","article-title":"Chronic dyspepsia: double-blind treatment with domperidone (R 33 812) or a placebo. A multicentre therapeutic evaluation.","volume":"23","author":"Van Ganse","year":"1978","journal-title":"Curr Therap Res"},{"issue":"suppl 1","key":"R161-10-20210210","first-page":"33","article-title":"Domperidone for the symptomatic treatment of chronic post-prandial nausea and vomiting.","volume":"55","author":"Van Outryve","year":"1979","journal-title":"Postgrad Med J"},{"key":"R162-10-20210210","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/j.1572-0241.2004.30086.x","article-title":"A systematic review of psychological therapies for nonulcer dyspepsia.","volume":"99","author":"Soo","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R163-10-20210210","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/16506078809456271","article-title":"Behavioural treatment of non-ulcer dyspepsia.","volume":"17","author":"Bates","year":"1988","journal-title":"Scand J Behav Ther"},{"key":"R164-10-20210210","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/gast.2002.37071","article-title":"Long-term improvement in functional dyspepsia using hypnotherapy.","volume":"123","author":"Calvert","year":"2002","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"R165-10-20210210","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S0016-5085(13)60724-6","article-title":"Significance of double steps reattribution integrative model for patients with functional dyspepsia (FD) (Abstract).","volume":"144","author":"Cao","year":"2013","journal-title":"Gastroenterology"},{"key":"R166-10-20210210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.psy.0000249734.99065.6f","article-title":"Flexible coping psychotherapy for functional dyspeptic patients: a randomized, controlled trial.","volume":"69","author":"Cheng","year":"2007","journal-title":"Psychosom Med"},{"key":"R167-10-20210210","first-page":"45","article-title":"The effectivenss of cognitive behavior stress management on functional dyspepsia symptoms.","volume":"3","author":"Dehghanizade","year":"2015","journal-title":"J Adv Med Educ Prof"},{"key":"R168-10-20210210","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajp.2012.12.012","article-title":"A randomized controlled trial of brief psychoanalytic psychotherapy in patients with functional dyspepsia.","volume":"6","author":"Faramarzi","year":"2013","journal-title":"Asian J Psych"},{"key":"R169-10-20210210","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2007.03277.x","article-title":"Is there a benefit from intensified medical and psychological interventions in patients with functional dyspepsia not responding to conventional therapy?","volume":"25","author":"Haag","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R170-10-20210210","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1053\/gast.2000.16493","article-title":"A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia.","volume":"119","author":"Hamilton","year":"2000","journal-title":"Gastroenterology"},{"key":"R171-10-20210210","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/0022-3999(94)90026-4","article-title":"Psychotherapy in functional dyspepsia.","volume":"38","author":"Haug","year":"1994","journal-title":"J Psychosom Res"},{"key":"R172-10-20210210","first-page":"52","article-title":"The effect of psychotherapy intervention on pharmacotherapy of patients with functional dyspepsia.","volume":"8","author":"Jiang","year":"2008","journal-title":"Pharm Care Res"},{"key":"R173-10-20210210","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.11569\/wcjd.v23.i24.3940","article-title":"Clinical effects of behavioral interventions in elderly patients with functional dyspepsia.","volume":"23","author":"Liu","year":"2015","journal-title":"World Chin J Digestol"},{"key":"R174-10-20210210","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpsychores.2015.03.003","article-title":"A randomized controlled trial of a 10 week group psychotherapeutic treatment added to standard medical treatment in patients with functional dyspepsia.","volume":"78","author":"Orive","year":"2015","journal-title":"J Psychosom Res"},{"key":"R175-10-20210210","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1046\/j.1365-2036.2003.01498.x","article-title":"Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia.","volume":"17","author":"Koloski","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"R176-10-20210210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/SGA.0b013e31819e4be7","article-title":"A qualitative study of complementary and alternative medicine use in persons with uninvestigated dyspepsia.","volume":"32","author":"Stake-Nilsson","year":"2008","journal-title":"Gastroenterol Nurs"},{"key":"R177-10-20210210","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1111\/j.1572-0241.2006.01183.x","article-title":"STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study.","volume":"102","author":"von Arnim","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R178-10-20210210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0254-6272(13)60063-1","article-title":"Meta-analysis of traditional Chinese medicine in treating functional dyspepsia of liver-stomach disharmony syndrome.","volume":"32","author":"Wang","year":"2012","journal-title":"J Tradit Chin Med"},{"key":"R180-10-20210210","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1053\/j.gastro.2004.05.030","article-title":"Pathophysiology and treatment of functional dyspepsia.","volume":"127","author":"Tack","year":"2004","journal-title":"Gastroenterology"},{"key":"R181-10-20210210","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jama.2007.51-a","article-title":"A 32-year-old woman with chronic abdominal pain.","volume":"299","author":"Lacy","year":"2008","journal-title":"JAMA"},{"key":"R182-10-20210210","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1038\/ajg.2012.104","article-title":"Functional dyspepsia and gastroparesis: One disease or two?","volume":"107","author":"Lacy","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R183-10-20210210","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2982.2011.01690.x","article-title":"Measurement of gastric accommodation: a reappraisal of conventional and emerging modalities.","volume":"23","author":"Ang","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"R184-10-20210210","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.cgh.2007.05.015","article-title":"Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study.","volume":"5","author":"Talley","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R185-10-20210210","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10620-007-0012-1","article-title":"Lack of relationship between chronic upper abdominal symptoms and gastric function in functional dyspepsia.","volume":"53","author":"van Lelyveld","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R186-10-20210210","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000175836","article-title":"Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy.","volume":"78","author":"Cassilly","year":"2008","journal-title":"Digestion"},{"key":"R187-10-20210210","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ajg.2012.373","article-title":"Clinical guideline: management of gastroparesis.","volume":"108","author":"Camilleri","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R188-10-20210210","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1053\/gast.1996.v110.pm8612991","article-title":"Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia.","volume":"110","author":"Stanghellini","year":"1996","journal-title":"Gastroenterology"},{"key":"R189-10-20210210","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1572-0241.2003.07389.x","article-title":"Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia.","volume":"98","author":"Sarnelli","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-201707000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:28:50Z","timestamp":1786544930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201707000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":172,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2017.154","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727734914.793546685","asserted-by":"object"}]},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}